LONDON (Reuters) -Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its experimental inflammatory disease drug amlitelimab fell short of Wall Street expectations.
(Reporting by Maggie FickEditing by Bernadette Baum)
Brought to you by www.srnnews.com